Novartis India gets BSE in-principle nod for ₹900 Cr rights issue

Novartis India Ltd (now Evonile Pharma Limited) has received in-principle approval from BSE Limited for its proposed rights issue. The company plans to raise up to ₹9,000.00 million (₹900 Crore) through the issuance of partly paid-up equity shares. A Board of Directors meeting is scheduled for November 04, 2026, to consider and approve the Letter of Offer for the rights issue. Additionally, the Rights Issue Committee will meet on the same day to finalize key details such as issue price, entitlement ratio, record date, and fractional entitlements. This follows the Board's earlier approval for the rights issue on October 08, 2026.